These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34893426)

  • 1. Potential effects and application prospect of angiotensin receptor-neprilysin inhibitor in diabetic kidney disease.
    Zhang X; Zhou Y; Ma R
    J Diabetes Complications; 2022 Jan; 36(1):108056. PubMed ID: 34893426
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Angiotensin Receptor Neprilysin Inhibitor Use and Blood Pressure Lowering in Patients With Heart Failure With Reduced Ejection Fraction Across the Spectrum of Kidney Function: An Analysis of the Veterans Administrative Health System.
    Gjyriqi G; York M; Abuazzam F; Herzog CA; Bangalore S; Lo KB; Sidhu MS; Vaduganathan M; Rangaswami J; Mathew RO
    J Card Fail; 2023 Mar; 29(3):258-268. PubMed ID: 36516938
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Updates for Cardio-Kidney Protective Effects by Angiotensin Receptor-Neprilysin Inhibitor: Requirement for Additional Evidence of Kidney Protection.
    Tsukamoto S; Uehara T; Azushima K; Wakui H; Tamura K
    J Am Heart Assoc; 2023 Apr; 12(8):e029565. PubMed ID: 37066800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Renal safety and efficacy of angiotensin receptor-neprilysin inhibitor: A meta-analysis of randomized controlled trials.
    Feng Y; Yin Y; Deng R; Li H
    J Clin Pharm Ther; 2020 Dec; 45(6):1235-1243. PubMed ID: 32776562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood pressure-independent renoprotection in diabetic rats treated with AT1 receptor-neprilysin inhibition compared with AT1 receptor blockade alone.
    Roksnoer LC; van Veghel R; Clahsen-van Groningen MC; de Vries R; Garrelds IM; Bhaggoe UM; van Gool JM; Friesema EC; Leijten FP; Hoorn EJ; Danser AH; Batenburg WW
    Clin Sci (Lond); 2016 Jul; 130(14):1209-20. PubMed ID: 27129187
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative effectiveness of traditional Chinese medicine and angiotensin converting enzyme inhibitors, angiotensin receptor blockers, and sodium glucose cotransporter inhibitors in patients with diabetic kidney disease: A systematic review and network meta-analysis.
    Zhang L; Miao R; Yu T; Wei R; Tian F; Huang Y; Tong X; Zhao L
    Pharmacol Res; 2022 Mar; 177():106111. PubMed ID: 35183713
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Dual Blockade of the Renin-Angiotensin-Aldosterone System in Diabetic Kidney Disease: A Meta-Analysis.
    Feng Y; Huang R; Kavanagh J; Li L; Zeng X; Li Y; Fu P
    Am J Cardiovasc Drugs; 2019 Jun; 19(3):259-286. PubMed ID: 30737754
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of angiotensin receptor-neprilysin inhibitor in suppression of ventricular arrhythmia.
    Tsai YN; Cheng WH; Chang YT; Hsiao YW; Chang TY; Hsieh YC; Lin YJ; Lo LW; Chao TF; Kuo MJ; Higa S; Chang SL; Chen SA
    J Cardiol; 2021 Oct; 78(4):275-284. PubMed ID: 34059408
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of diabetic kidney disease. A network meta-analysis.
    Büttner F; Barbosa CV; Lang H; Tian Z; Melk A; Schmidt BMW
    PLoS One; 2023; 18(11):e0293183. PubMed ID: 37917640
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Update on role of direct renin inhibitor in diabetic kidney disease.
    Dhakarwal P; Agrawal V; Kumar A; Goli KM; Agrawal V
    Ren Fail; 2014 Jul; 36(6):963-9. PubMed ID: 24678880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. To RAS or not to RAS? The evidence for and cautions with renin-angiotensin system inhibition in patients with diabetic kidney disease.
    St Peter WL; Odum LE; Whaley-Connell AT
    Pharmacotherapy; 2013 May; 33(5):496-514. PubMed ID: 23576066
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure.
    Macdonald PS
    Clin Ther; 2015 Oct; 37(10):2199-205. PubMed ID: 26386501
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neprilysin inhibition in chronic kidney disease.
    Judge P; Haynes R; Landray MJ; Baigent C
    Nephrol Dial Transplant; 2015 May; 30(5):738-43. PubMed ID: 25140014
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical and Socioeconomic Determinants of Angiotensin Receptor-Neprilysin Inhibitor Prescription at Hospital Discharge in Patients With Heart Failure With Reduced Ejection Fraction.
    Tran JS; Loveland MG; Alamer A; Piña IL; Sweitzer NK
    Circ Heart Fail; 2022 Nov; 15(11):e009395. PubMed ID: 36378759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Estimated 5-Year Number Needed to Treat to Prevent Cardiovascular Death or Heart Failure Hospitalization With Angiotensin Receptor-Neprilysin Inhibition vs Standard Therapy for Patients With Heart Failure With Reduced Ejection Fraction: An Analysis of Data From the PARADIGM-HF Trial.
    Srivastava PK; Claggett BL; Solomon SD; McMurray JJV; Packer M; Zile MR; Desai AS; Rouleau JL; Swedberg K; Fonarow GC
    JAMA Cardiol; 2018 Dec; 3(12):1226-1231. PubMed ID: 30484837
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential of Renin-Angiotensin-Aldosterone System Modulations in Diabetic Kidney Disease: Old Players to New Hope!
    Malek V; Suryavanshi SV; Sharma N; Kulkarni YA; Mulay SR; Gaikwad AB
    Rev Physiol Biochem Pharmacol; 2021; 179():31-71. PubMed ID: 32979084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Angiotensin receptor neprilysin inhibition provides superior cardioprotection compared to angiotensin converting enzyme inhibition after experimental myocardial infarction.
    Kompa AR; Lu J; Weller TJ; Kelly DJ; Krum H; von Lueder TG; Wang BH
    Int J Cardiol; 2018 May; 258():192-198. PubMed ID: 29544929
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variation in use and dosing escalation of renin angiotensin system, mineralocorticoid receptor antagonist, angiotensin receptor neprilysin inhibitor and beta-blocker therapies in heart failure and reduced ejection fraction: Association of comorbidities.
    Albert NM; Tyson RJ; Hill CL; DeVore AD; Spertus JA; Duffy C; Butler J; Patterson JH; Hernandez AF; Williams FB; Thomas L; Fonarow GC
    Am Heart J; 2021 May; 235():82-96. PubMed ID: 33497697
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-World Diagnosis and Treatment of Diabetic Kidney Disease.
    Rodriguez F; Lee DJ; Gad SS; Santos MP; Beetel RJ; Vasey J; Bailey RA; Patel A; Blais J; Weir MR; Dash R
    Adv Ther; 2021 Aug; 38(8):4425-4441. PubMed ID: 34254257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neprilysin inhibition to treat heart failure: a tale of science, serendipity, and second chances.
    McMurray JJ
    Eur J Heart Fail; 2015 Mar; 17(3):242-7. PubMed ID: 25756942
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.